pegylated top1 inhibitor peel-224
Generic: Pegylated TOP1 Inhibitor PEEL-224
pegylated top1 inhibitor peel-224: 1 clinical trial tracked.
pegylated top1 inhibitor peel-224 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about pegylated top1 inhibitor peel-224, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas
Primary endpoint: Maximum Tolerated Dose (MTD) (Phase 1)
Interventionalopen63 targetStarted 2025-01Completion 2029-093 sites · United StatesDavid S Shulman, MD